Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advanz Zeroes In On Innovative Assets And M&A

Business Has Increased In Value To Around €670m

Executive Summary

Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.

You may also be interested in...



Burden Departs Advanz As Intercept Deal Completes

As Advanz completes its deal to acquire Intercept’s ex-US business, the company has confirmed a management change that has seen chief commercial officer Paul Burden leave the company, with the appointment of two new regional CCOs.

PBMs’ ‘Perverse Incentives’ Still Limiting Generics Access, AAM Report Reiterates

Generic medicines continue to be intentionally left off formulary tiers in favor of more expensive brand medications, according to a new report from the US Association for Accessible Medicines.

Generic Mifepristone Manufacturer Sues West Virginia Over Abortion Ban

Generic abortion pill manufacturer GenBioPro has mounted a case in West Virginia alleging that its state-level ban of abortion is unconstitutional, as it is pre-empted by the US Food and Drug Administration’s federal opinion that mifepristone is a safe and legal medication.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel